Literature DB >> 15475752

Epstein-Barr virus-associated lymphoma in Crohn's disease.

Alessandra Losco1, Umberto Gianelli, Barbara Cassani, Luca Baldini, Dario Conte, Guido Basilisco.   

Abstract

Although no increased risk of developing lymphoproliferative disorders has been observed in population-based studies of patients with Crohn's disease, the possibility has been suggested in the subset of patients previously treated with thiopurine metabolites and suffering from concomitant Epstein-Barr virus infection. A few cases of lymphomas have occurred in patients with Crohn's disease treated with infliximab, only one of whom showed the presence of the Epstein-Barr virus genome. We here describe the case of a patient with steroid-dependent ileal Crohn's disease treated with azathioprine and a single infusion of infliximab, who developed a diffuse large B cell ileal lymphoma. Epstein-Barr virus genome was detected in the neoplastic cells by means of polymerase chain reaction. Epstein-Barr virus may be detected in the neoplastic tissues of lymphomas of patients with Crohn's disease treated with immunosuppressants and infliximab. The identification of such cases may help to define the frequency of this association and how to manage the lymphoproliferative disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475752     DOI: 10.1097/00054725-200407000-00015

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

Review 1.  What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Authors:  Gianluca Andrisani; Alessandro Armuzzi; Manuela Marzo; Carla Felice; Daniela Pugliese; Alfredo Papa; Luisa Guidi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

2.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

Review 3.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

4.  Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive.

Authors:  Emily McKeown; Janet E Pope; Suzanne Leaf
Journal:  Open Rheumatol J       Date:  2009-07-13

5.  EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?

Authors:  Patrick B Allen; Georgina Laing; Aoife Connolly; Ciaran O'Neill
Journal:  BMJ Case Rep       Date:  2013-09-30

6.  Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn's disease.

Authors:  Y N'guyen; L Andreoletti; M Patey; C Lecoq-Lafon; P Cornillet; A Léon; R Jaussaud; C Fieschi; C Strady
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

7.  Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy.

Authors:  Michael D Chang; Merry-Jennifer Markham; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2016-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.